Published today in Nature Medicine: Peptomyc’s first MYC inhibitor, OMO-103, demonstrates safety and anti-tumor activity in a phase I clinical trial

On February 6, 2024 Peptomyc reported that the results of the MYCure clinical trial have just been published in Nature Medicine (View Source), demonstrating the unique potential of its lead first-in-class MYC inhibitor, OMO-103, to treat multiple oncological indications (Press release, Peptomyc, FEB 6, 2024, View Source [SID1234639882]). Peptomyc takes pride in pioneering the blockade of a most-wanted target in cancer, and we believe this encouraging data, along with our preclinical findings, underscore the importance of MYC inhibition in the treatment of cancer.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Thanks to the whole team, to our investors and collaborators for believing in this work and for this huge milestone!